Categories Earnings, Health Care

Sanofi (NASDAQ: SNY): Q4 2019 Earnings Snapshot

— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.

— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.

— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.

— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.

— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.

— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.

— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.

— SNY stock was up about 4% in the pre-market trading session.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Most Popular

Adobe (ADBE) Q2 adjusted earnings rise on higher revenues

Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in revenue and adjusted profit for the second quarter of 2025, amid continued growth in its subscription-based business. The design software

ORCL Earnings: Highlights of Oracle’s Q4 2025 financial report

Technology giant Oracle Corporation (NYSE: ORCL) has reported higher revenues and adjusted earnings for the fourth quarter of 2025. Total revenues increased to $15.9 billion in the May quarter from

Key highlights from Chewy’s (CHWY) Q1 2025 earnings results

Chewy, Inc. (NYSE: CHWY) reported its first quarter 2025 earnings results today. Net sales of $3.12 billion increased 8.3% year-over-year. Net income decreased 6.7% to $62.4 million compared to last

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top